Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK

被引：2
|
作者：
Dodkins, J. [1 ]
Cook, A. [1 ]
Nossiter, J. [1 ]
Payne, H. A. [2 ]
Clarke, N. W. [3 ]
van der Meulen, J. [4 ]
Aggarwal, A. [4 ]
机构：
[1] Royal Coll Surgeons England, Clin Effectiveness Unit, London, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, London, England
[3] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England
[4] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1790P
引用
收藏
页码：S967 / S967
页数：1
相关论文
共 50 条
  • [41] Metastatic hormone sensitive prostate cancer: local treatment strategies
    Jochen Walz
    Geraldine Pignot
    Sami Fakhfakh
    Jennifer Campagna
    Mathilde Guerin
    Cecile Vicier
    Serge Brunelle
    Naji Salem
    Gwenaelle Gravis
    World Journal of Urology, 2021, 39 : 327 - 337
  • [42] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
    Li, Hengping
    Zhang, Mao
    Wang, Xiangrong
    Liu, Yang
    Li, Xuanpeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
    Halabi, S.
    Luo, B.
    Guo, S.
    Rydzewska, L. H. M.
    Godolphin, P. J.
    Parmar, M. K.
    Carducci, M. A.
    Gravis, G.
    James, N. D.
    Tierney, J. F.
    Sweeney, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S975 - S975
  • [44] Optimal treatment for metastatic hormone-sensitive prostate cancer
    Omlin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
  • [45] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [46] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
  • [47] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [48] AN INFLECTION POINT IN REAL-WORLD TREATMENT INTENSIFICATION FOR MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN THE UNITED STATES (US): RESULTS FROM PATIENT CHART REVIEWS
    Grossman, J.
    Chen, S.
    Goebell, P. J.
    VALUE IN HEALTH, 2024, 27 (06) : S367 - S367
  • [49] Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
    Garcia De Herreros, M.
    Jimenez Blasco, N.
    Reig Torras, O.
    Ferrer Mileo, L.
    Aversa, C.
    Garcia-Esteve, S.
    Rodriguez-Carunchio, L.
    Trias Puigsureda, I.
    Padrosa, J.
    Fernandez Manas, L.
    Marin, M.
    Font Pous, A.
    Rodriguez-Vida, A.
    Climent Duran, M. A.
    Cros Costa, S.
    Chirivella Gonzalez, I.
    Figols Gorina, M.
    Mellado Gonzalez, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S992 - S992
  • [50] Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC).
    Alex, Anitha
    Stenehjem, David D.
    Twardowski, Przemyslaw
    Cheng, Heather H.
    Buckley, Tyler Howard
    Gill, David
    Patel, Shiven B.
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345